Stretched
Senior Member
- Messages
- 712
- Location
- U.S. Atlanta
Reviewed by Barchart, Stock on NY Stock Exchange: NNVC
Ultra-Broad-Spectrum Antiviral Nanomedicines Enabled by the This Public Company’s Revolutionary Platform Would Open Up Very Large Market Opportunities
The company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market. We’re talking a single drug that could treat covid, RSV, the flu, and even monkey pox. And this drug has just successfully completed phase 1 clinical trials.
NV-387’s extremely broad antiviral is a host mimetic that acts as a decoy to attract and trap many diverse viruses, preventing the virus from replication and reinfection of other cells.
In laymen’s terms, NV-387 could revolutionize antiviral treatment just as antibiotics did against bacteria. Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants.
NV-387 could change medicine as we know it. Still, it is just one drug in this organization’s promising product pipeline.
Thus, this company should be at the top of your watchlist. Read more now.
Ultra-Broad-Spectrum Antiviral Nanomedicines Enabled by the This Public Company’s Revolutionary Platform Would Open Up Very Large Market Opportunities
The company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market. We’re talking a single drug that could treat covid, RSV, the flu, and even monkey pox. And this drug has just successfully completed phase 1 clinical trials.
NV-387’s extremely broad antiviral is a host mimetic that acts as a decoy to attract and trap many diverse viruses, preventing the virus from replication and reinfection of other cells.
In laymen’s terms, NV-387 could revolutionize antiviral treatment just as antibiotics did against bacteria. Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants.
NV-387 could change medicine as we know it. Still, it is just one drug in this organization’s promising product pipeline.
Thus, this company should be at the top of your watchlist. Read more now.
Last edited: